EUVIMEDExplore EUVIMED
Crossref

Human induced pluripotent stem cell‐derived chimeric antigen receptor‐macrophages eradicate IL ‐ 13Rα2 ‐positive solid tumors

Ying Yang, Lujing Wang, Yi Zhang, Shuzhen Lyu, Qianying Ruan, Chao Wang, Feiyue Dou, Gongbo Liang, Guangning Yan, Mengru Wang, Haizhen Fan, Haoyue Qi and 18 more

The Journal of Pathology · 2026

DOI: 10.1002/path.70063 ↗

At a glance

Journal article in The Journal of Pathology, 2026. Written by Ying Yang and 29 co-authors. Institution: Institute of Pathology & Southwest Cancer Center, the First Affiliated Hospital (Southwest Hospital) and School of Basic Medical Sciences, Army Medic…. Major MEDLINE topics: Interleukin-13 Receptor alpha2 Subunit, Induced Pluripotent Stem Cells, Immunotherapy, Adoptive, Receptors, Chimeric Antigen. Cited 2 times so far (Crossref); 59 references. Funded by: Chongqing Municipal Science and Technology Bureau, National Natural Science Foundation of China, Chongqing Municipal Health Commission.

AbstractSubjectsBibliographic detailsCiteRelated studies

Abstract (original language)

Macrophages exhibit extensive tumor infiltration capacity across diverse solid malignancies, establishing macrophage‐targeted immunotherapies as an emerging frontier in oncology. Genetic engineering of macrophages using chimeric antigen receptor (CAR) technology − enabling recognition and phagocytosis of neoplastic cells − is emerging as a potential therapeutic strategy against solid tumors. Human induced pluripotent stem cells (iPSCs) provide a renewable platform for the efficient differentiation of functionally competent macrophages. In this study, we engineered human iPSC‐derived CAR macrophages (iCAR‐M) targeting interleukin‐13 receptor subunit alpha 2 (IL‐13Rα2). Pan‐tumor transcriptomic and immunohistochemical analyses revealed that IL‐13Rα2, a tumor‐associated antigen, was overexpressed in human glioblastoma (GBM), uterine carcinosarcoma (UCS), and melanoma specimens. In vitro phagocytosis assays revealed target‐specific clearance of IL‐13Rα2‐positive tumor cells by iCAR‐M. Intracranial administration of iCAR‐M potently suppressed tumor growth, enhanced intratumoral cytotoxic T‐cell infiltration, and prolonged the survival of humanized, immunocompetent mice bearing GBM xenografts. The administered iCAR‐M maintained phagocytic capacity in vivo and acquired an M1‐like pro‐inflammatory phenotype. Comprehensive safety assessment revealed no detectable evidence of systemic toxicity or treatment‐related neurotoxicity. Collectively, these results demonstrate the potent efficacy and favorable safety profile of iPSC‐derived, IL‐13Rα2‐targeted CAR macrophages, supporting their therapeutic potential against solid tumors. © 2026 The Pathological Society of Great Britain and Ireland.

Subjects

MeSH terms (MEDLINE)

Interleukin-13 Receptor alpha2 SubunitInduced Pluripotent Stem CellsImmunotherapy, AdoptiveReceptors, Chimeric AntigenGlioblastomaMacrophagesHumansAnimalsPhagocytosisXenograft Model Antitumor AssaysCell Line, TumorFemaleMice

Author keywords

chimeric antigen receptor macrophagesglioblastomaimmune therapyinduced pluripotent stem cellsinterleukin‐13 receptor subunit alpha‐2

Substances

Interleukin-13 Receptor alpha2 SubunitIL13RA2 protein, humanReceptors, Chimeric Antigen

Authors and institutions

  • Institute of Pathology & Southwest Cancer Center, the First Affiliated Hospital (Southwest Hospital) and School of Basic Medical Sciences, Army Medical University (Third Military Medical University), and the Key Laborat…
  • State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sc…
  • Department of Blood Transfusion, the First Affiliated Hospital (Southwest Hospital), Army Medical University (Third Military Medical University), Chongqing, PR China.
  • Department of Pathology, General Hospital of Southern Theater Command, People's Liberation Army of PR China, Guangzhou, PR China.
  • School of Medicine, Chongqing University, Chongqing, PR China.
  • Chongqing Yuyue Scientific Research Center for Pathology, Chongqing Institute of Advanced Pathology, Jinfeng Laboratory, Chongqing, PR China.

ORCID profiles: Yi-Fang Ping, Xiu-Wu Bian, Yu Shi

Funding

  • Chongqing Municipal Science and Technology Bureau
  • National Natural Science Foundation of China
  • Chongqing Municipal Health Commission
  • National Key Research and Development Program of China
  • Natural Science Foundation of Chongqing Municipality

Cite

APA

Yang, Y., Wang, L., Zhang, Y., Lyu, S., Ruan, Q., Wang, C., Dou, F., Liang, G., Yan, G., Wang, M., Fan, H., Qi, H., Kong, W., Guo, H., Liu, Q., Wang, W., Mao, M., Huang, Y., Zhou, X., …, & Shi, Y. (2026). Human induced pluripotent stem cell‐derived chimeric antigen receptor‐macrophages eradicate IL ‐ 13Rα2 ‐positive solid tumors. The Journal of Pathology. https://doi.org/10.1002/path.70063

Vancouver

Yang Y, Wang L, Zhang Y, Lyu S, Ruan Q, Wang C, et al. Human induced pluripotent stem cell‐derived chimeric antigen receptor‐macrophages eradicate IL ‐ 13Rα2 ‐positive solid tumors. The Journal of Pathology. 2026. doi:10.1002/path.70063

BibTeX
@article{Yang2026,
  author = {Yang, Ying and Wang, Lujing and Zhang, Yi and Lyu, Shuzhen and Ruan, Qianying and Wang, Chao and Dou, Feiyue and Liang, Gongbo and Yan, Guangning and Wang, Mengru and Fan, Haizhen and Qi, Haoyue and Kong, Weikai and Guo, Haitao and Liu, Qing and Wang, Wenying and Mao, Min and Huang, Yuxi and Zhou, Xinyue and Duan, Jiayu and Song, Wangyang and Huang, Bangguo and Cheng, Yuhui and Zhou, Lei and Xu, Senlin and Shen, Jun and Ping, Yi-Fang and Bian, Xiu-Wu and He, Zhicheng and Shi, Yu},
  title = {Human induced pluripotent stem cell‐derived chimeric antigen receptor‐macrophages eradicate IL ‐ 13Rα2 ‐positive solid tumors},
  journal = {The Journal of Pathology},
  year = {2026},
  doi = {10.1002/path.70063}
}
Start for free →